Amvuttra (vutrisiran)

Amvuttra (vutrisiran) is covered for adults with hereditary transthyretin-mediated (hATTR) polyneuropathy when genetic testing confirms a transthyretin mutation, the patient has symptomatic polyneuropathy, is ≥18 years old, has no history of liver transplantation, the prescription is by or in consultation with a neurologist/geneticist/amyloidosis specialist, and treatment is for the FDA‑approved indication (approvals for 12 months; recommended dosing 25 mg SC every 3 months). Excluded are patients <18, asymptomatic mutation carriers, those without a confirmed TTR mutation, individuals with prior liver transplant, and requests not involving an authorized specialist.

"Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults."

Sign up to see full coverage criteria, indications, and limitations.